Global Hepatitis B Human Immunoglobulin Market Research Report 2022

Due to the COVID-19 pandemic, the global Hepatitis B Human Immunoglobulin market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Hepatitis B Human Immunoglobulin market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Hepatitis B Human Immunoglobulin landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
100IU accounting for % of the Hepatitis B Human Immunoglobulin global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Measles Prevention segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Hepatitis B Human Immunoglobulin include Biotest, ADMA Biologics, Sanquin Blood, Bio Products Laboratory, Baxter, CSL, Bayer, Grifols and Octapharma, etc. In terms of revenue, the global 3 largest players have a % market share of Hepatitis B Human Immunoglobulin in 2021.
This report focuses on Hepatitis B Human Immunoglobulin volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Hepatitis B Human Immunoglobulin market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Hepatitis B Human Immunoglobulin Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
100IU
200IU
400IU
Segment by Application
Measles Prevention
Prevention of Hepatitis B Virus Infection
Hepatitis A Virus Infection
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Biotest
ADMA Biologics
Sanquin Blood
Bio Products Laboratory
Baxter
CSL
Bayer
Grifols
Octapharma
Hualan Biological
China Biologic
Tiantan Biologic
Shuanglin Bio-pharmacy
Sichuan Yuanda Shuyang
Shanghai Institute of Biological
Hualan
Shanghai RAAS Blood Products
China Grand Enterprises
Nanyue Biopharmaceutical
Boya Biopharmaceutical Group
Tonglu Biopharmaceutical
Shandong Taibang Biopharmaceutical
Guangdong Shuanglin Biopharmaceutical
Chengdu Rongsheng Pharmaceutical
Shenzhen Weiguang Biopharmaceutical
Green Cross (China) Biological Products
Sinopharm